Junevity

The company's central asset is its proprietary RESET™ platform, which utilizes large-scale human data and artificial intelligence to identify transcription factors that regulate cellular damage. Once identified, Junevity develops novel small interfering RNA (siRNA) therapeutics designed to repress these specific transcription factors, aiming to restore cellular transcription to a healthier state. This 'Cell Reset' approach is engineered to treat the underlying biology of complex diseases associated with aging. The firm's business model involves advancing its own clinical programs while also forming partnerships with pharmaceutical companies to co-develop new cell reset siRNA therapeutics. Revenue generation is anticipated from the successful development and commercialization of these therapies.

Junevity's primary therapeutic focus is on conditions that affect a large portion of the global population, including Type 2 diabetes, obesity, and frailty. The company has announced preclinical data for its programs in Type 2 diabetes and obesity. The siRNA therapeutics are being developed for infrequent dosing, potentially every three to twelve months, which could enhance patient compliance. In February 2025, Junevity announced it had secured $10 million in seed funding led by Goldcrest Capital and Godfrey Capital to advance the RESET™ platform and its initial therapeutic candidates.